Management of symptomatic, untreated chronic lymphocytic leukemia

Blood Reviews

Volumn 21, Issue 3, 2007, Pages 143-156

  Kasamon, Yvette L ^a   Flinn, Ian W ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia (CLL); Fludarabine; Rituximab

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PENTOSTATIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HERPES; HUMAN; IMMUNOTHERAPY; INFECTION; LYMPHOCYTOPENIA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE MANAGEMENT; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; RISK ASSESSMENT; TREATMENT OUTCOME; VIDARABINE;

EID: 34047190281     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2006.10.001     Document Type: Article

References (84)

1. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 87 (1996) 4990-4997
2. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood. 1990;75:1414-1421.
3. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst. 1999;91:861-868.
4. Hamblin T.J. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 33 (2006) 230-239
5. Rozman C., Montserrat E., Rodriguez-Fernandez J.M., et al. Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 64 (1984) 642-648
6. Molica S., and Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer. 60 (1987) 2712-2716
7. Hallek M., Wanders L., Ostwald M., et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 22 (1996) 439-447
8. Dohner H., Fischer K., Bentz M., et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 85 (1995) 1580-1589
9. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 343 (2000) 1910-1916
10. Krober A., Seiler T., Benner A., et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 100 (2002) 1410-1416
11. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 351 (2004) 893-901
12. Montserrat E., Alcala A., Parody R., et al. Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone. Cancer. 56 (1985) 2369-2375
13. Keller J.W., Knospe W.H., Raney M., et al. Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A Southeastern Cancer Study Group Trial. Cancer 58 (1986) 1185-1192
14. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 343 (2000) 1750-1757
15. Sawitsky A., Rai K.R., Glidewell O., and Silver R.T. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. 50 (1977) 1049-1059
16. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood. 1990;75:1422-1425.
17. Raphael B., Andersen J.W., Silber R., et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol. 9 (1991) 770-776
18. Leporrier M., Chevret S., Cazin B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 98 (2001) 2319-2325
19. Keating M.J., Kantarjian H., O'Brien S., et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol. 9 (1991) 44-49
20. O'Brien S., Kantarjian H., Beran M., et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 82 (1993) 1695-1700
21. Johnson S., Smith A.G., Loffler H., et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 347 (1996) 1432-1438
22. Eichhorst B.F., Busch R., Wendtner C.M., and Hallek M. Comparison of the efficacy and toxicity of fludarabine (F) in first line therapy of younger versus elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a meta-analysis of two phase III trials of the German CLL Study Group (GCLLSG) [abstract]. Blood. 106 (2005) abstract 717
23. Robak T., Blonski J.Z., Kasznicki M., et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit. 11 (2005) PI71-PI79
24. Saven A., Lemon R.H., Kosty M., Beutler E., and Piro L.D. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol. 13 (1995) 570-574
25. Karisson K., Stromberg M., Jonsson V., et al. Cladribine (CdA) or fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia? First interim analysis of data from the international randomized phase III trial [abstract]. Blood. 104 (2004) abstract 3470
26. Dillman R.O., Mick R., and McIntyre O.R. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol. 7 (1989) 433-438
27. Morrison V.A., Rai K.R., Peterson B.L., et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 19 (2001) 3611-3621
28. Keating M.J., O'Brien S., Lerner S., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 92 (1998) 1165-1171
29. Flinn I.W., Byrd J.C., Morrison C., et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 96 (2000) 71-75
30. Ketterer N., Salles G., Moullet I., et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol. 103 (1998) 235-242
31. Micallef I.N., Apostolidis J., Rohatiner A.Z., et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J. 1 (2000) 367-373
32. Tournilhac O., Cazin B., Lepretre S., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 103 (2004) 363-365
33. Montillo M., Tedeschi A., Rossi V., et al. Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H. Leukemia. 18 (2004) 57-62
34. Lysak D., Koza V., Steinerova K., Jindra P., Vozobulova V., and Schutzova M. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol. 84 (2005) 456-461
35. Taha H.M., Narasihman P., Venkatesh L., Cawley M., and Kaplan B. Fludarabine-related hemolytic anemia in chronic lymphocytic leukemia and lymphoproliferative disorders. Am J Hematol. 59 (1998) 316
36. Myint H., Copplestone J.A., Orchard J., et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 91 (1995) 341-344
37. Plunkett W., Gandhi V., Huang P., et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 20 (1993) 2-12
38. Johnston J.B., Verburg L., Shore T., Williams M., Israels L.G., and Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia. 8 Suppl 1 (1994) S140-S143
39. O'Brien S.M., Kantarjian H.M., Cortes J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 19 (2001) 1414-1420
40. Hochster H.S., Oken M.M., Winter J.N., et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up-a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 18 (2000) 987-994
41. Schiavone E.M., De Simone M., Palmieri S., et al. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. Eur J Haematol. 71 (2003) 23-28
42. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 107 (2006) 885-891
43. Flinn I.W., Kumm E., Grever M.R., et al. Fludarabine and cyclophosphamide produces a higher complete response rate and more durable remissions than fludarabine in patients with previously untreated CLL: Intergroup Trial E2997 [abstract]. Blood. 104 (2004) abstract 475
44. Morrison V.A., Rai K.R., Peterson B.L., et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 20 (2002) 3878-3884
45. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 19 (2001) 2153-2164
46. Byrd J.C., Peterson B.L., Morrison V.A., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 101 (2003) 6-14
47. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 16 (1998) 2825-2833
48. Nguyen D.T., Amess J.A., Doughty H., Hendry L., and Diamond L.W. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol. 62 (1999) 76-82
49. Foran J.M., Rohatiner A.Z., Cunningham D., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 18 (2000) 317-324
50. Berinstein N.L., Grillo-Lopez A.J., White C.A., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 9 (1998) 995-1001
51. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V., and Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 94 (1999) 2217-2224
52. Hainsworth J.D., Litchy S., Barton J.H., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 21 (2003) 1746-1751
53. Hainsworth J.D., Litchy S., Burris III H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 20 (2002) 4261-4267
54. Thomas D.A., O'Brien S., Giles F.J., et al. Single-agent Rituxan in early stage chronic lymphocytic leukemia (CLL) [abstract]. Blood. 98 (2001) abstract 1533
55. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 23 (2005) 4079-4088
56. Byrd J.C., Gribben J.G., Peterson B.L., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 24 (2006) 437-443
57. Del Poeta G., Del Principe M.I., Consalvo M.A., et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer. 104 (2005) 2743-2752
58. Byrd J.C., Rai K., Peterson B.L., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 105 (2005) 49-53
59. Flinn I.W., Jemiai Y., and Bennett J.M. Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: E1997 [abstract]. Blood. 98 (2001) abstract 2649
60. Osterborg A., Fassas A.S., Anagnostopoulos A., Dyer M.J., Catovsky D., and Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 93 (1996) 151-153
61. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 100 (2002) 768-773
62. Lundin J., Porwit-MacDonald A., Rossmann E.D., et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 18 (2004) 484-490
63. O'Brien S.M., Kantarjian H.M., Thomas D.A., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 98 (2003) 2657-2663
64. Rai K.R., Byrd J.C., Peterson B., Gautier M., and Larson R.A. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901 [abstract]. Blood. 102 (2003) abstract 2506
65. Wendtner C.M., Ritgen M., Schweighofer C.D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 18 (2004) 1093-1101
66. Montillo M., Tedeschi A., Miqueleiz S., et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 24 (2006) 2337-2342
67. el Rouby S., Thomas A., Costin D., et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 82 (1993) 3452-3459
68. Byrd J.C., Smith L., Hackbarth M.L., et al. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. Cancer Res. 63 (2003) 36-38
69. Cano I., Martinez J., Quevedo E., et al. Trisomy 12 and p53 deletion in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: association with morphology and resistance to conventional chemotherapy. Cancer Genet Cytogenet. 90 (1996) 118-124
70. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 103 (2004) 3278-3281
71. Stilgenbauer S., Krober A., Winkler D., et al. VH mutation status and genomic aberrations in the prospective CLL1 Trial (Binet-A) of the German CLL Study Group (GCLLSG) [abstract]. Blood. 100 (2002) abstract 628
72. Grever M.R., Lucas D.M., Dewald G.W., et al. Outcome of treatment with fludarabine versus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) is adversely impacted by high risk genetic features: results from ECOG 2997 [abstract]. Blood. 104 (2004) abstract 3487
73. Catovsky D., Richards S., Matutes E., et al. Response to therapy and survival in CLL is influenced by genetic markers. Preliminary analysis from the LRF CLL4 trial [abstract]. Blood. (2004) 104
74. Kay N.E., Greyer S.M., Lin T., et al. Combination chemotherapy with pentostatin, cyclophosphamide, and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia [abstract]. Blood. 104 (2004) abstract 339
75. Stilgenbauer S., Krober A., Busch R., et al. 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 Trial of the GCLLSG [abstract]. Blood. 106 (2005) abstract 715
76. Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 106 (2005) 4389-4396
77. Sorror M.L., Maris M.B., Sandmaier B.M., et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 23 (2005) 3819-3829
78. Michallet M., Archimbaud E., Bandini G., et al. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Intern Med. 124 (1996) 311-315
79. Dreger P., Brand R., Milligan D., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 19 (2005) 1029-1033
80. Ritgen M., Stilgenbauer S., von Neuhoff N., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 104 (2004) 2600-2602
81. Ritgen M., Lange A., Stilgenbauer S., et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood. 101 (2003) 2049-2053
82. Dreger P., Stilgenbauer S., Benner A., et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. Blood. 103 (2004) 2850-2858
83. Berdeja J.G., Jones R.J., Zahurak M.L., et al. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant. 7 (2001) 561-567
84. Schulz H., Klein S.K., Rehwald U., et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 100 (2002) 3115-3120